Teva Pharmaceutical Industries (NYSE:TEVA) FY Conference December 03, 2025 08:20 AM ET Speaker0 All right, thank you guys for being here. Richard, thank you for making time. Super excited to have you back. Always enjoy spending time. First of all, huge congratulations on Austedo price point. It was the lowest on the HHS list. How did you guys make that happen? Speaker2 It's strange that people have been congratulating me for a price decrease, which seems counterintuitive and sort of a bit. So the way we did ...

Highlights The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinibThe patent extends protection for narmafotinib to at least 2040 Melbourne, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has received formal notification from the US Patent and Trademark Office (USPTO) that a key patent titled A salt and crystal form of a FAK Inhi ...

and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. DDR genes as strong predictors of LP-184 sensitivity.LP-184 functions as a prodrug that is selectively activated inside cancer cells by PTGR1, which is fr ...

Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platformSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjuga ...

Group 1 - The CEO of Sanofi expresses excitement about his role and upcoming readouts that will determine the success of his leadership [2] - Sanofi's CEO received a personal letter from the President of the United States, which is a rare occurrence for corporate leaders [2] - The letter from the President requested 17 companies, including Sanofi, to voluntarily adjust their prices in favor of the United States, indicating a push for industry cooperation rather than legislation [3]

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players ...

Key Points These two market leaders boast significant growth prospects in their niches. They increased their payouts at a good clip over the past decade. 10 stocks we like better than Microsoft › Most companies worth $1 trillion or more are leaders in their respective industries and boast excellent long-term growth prospects. Hardly any of them are known for their dividends, but several do offer competitive income programs that arguably make them even more attractive. That's the case with Microsoft ...

Fort Lauderdale, FL, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Drugs Made In America Acquisition II Corp. (the “Company”), a special purpose acquisition company formed as a Cayman Islands exempted company, today announced that commencing December 3, 2025, holders of the units sold in the Company’s initial public offering completed on September 26, 2025, may elect to separately trade the ordinary shares of the Company and the rights included in such units on the Nasdaq Global Market tier of The Nasdaq Stock Market L ...

Cosmo Pharmaceuticals shares soared the most in 17 years after the company said its experimental treatment for male hair loss showed breakthrough results in two studies https://t.co/Xqy5xuPxa9 ...